Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Multi-cohort Trial of Neoadjuvant and Post-surgery IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Selected Resectable Tumors

NCT05280314 is registered in ClinicalTrials.gov with IO Biotech as lead sponsor.

NCT NCT05280314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05280314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Multi-cohort Trial of Neoadjuvant and Post-surgery IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Selected Resectable Tumors
Lead sponsor
IO Biotech
Phase
Phase 2
Overall status
Recruiting
Start date
December 21, 2023
Completion date
January 31, 2027
Enrollment
60 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, squamous cell carcinoma of head and neck